Market Overview:
The global biosurgery market size reached US$ 13.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.1 Billion by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032.
Report Attribute
|
Key Statistics
|
Base Year
|
2023
|
Forecast Years
|
2024-2032
|
Historical Years
|
2018-2023
|
Market Size in 2023
|
US$ 13.9 Billion |
Market Forecast in 2032
|
US$ 24.1 Billion |
Market Growth Rate (2024-2032) |
6.1% |
Biosurgery is a medical procedure that involves the use of natural, synthetic or semi-synthetic materials to seal surgical incisions and wounds. It is widely used for preventing excessive blood loss, providing adhesion for wound or tissue sealing and repairing damaged tissues and bones. Biosurgeries are usually conducted through various hemostatic, sealant, soft tissue repair, bone graft substitute, adhesion prevention and staple line reinforcement products. They also utilize natural allografts, cultured epithelial autografts and xenografts for minimizing intra and post-operative complications and promoting faster recovery of the patients. As a result, they are widely used for neurological, cardiovascular, orthopedic, spinal, thoracic and reconstruction surgeries.
Biosurgery Market Trends:
The increasing prevalence of musculoskeletal disorders that require treatment through surgical procedures is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more prone to osteoporosis and other chronic medical ailments, is providing a thrust to the market growth. Patients and healthcare providers are widely adopting biosurgeries for effective blood loss management in patients through minimally invasive (MI) hemostatic agents and surgical sealants in place of traditionally used sutures and staples. In line with this, the rising incidents of sports-related injuries and accidental traumas is also contributing to the growth of the market. Additionally, various technological advancements, such as the development of plasma-based, multi-functional and multi-use products for biosurgeries, are favoring the growth of the market. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biosurgery market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, source, application and end user.
Breakup by Product:
- Bone-Graft Substitutes
- Soft-Tissue Attachments
- Hemostatic Agents
- Surgical Sealants and Adhesives
- Adhesion Barriers
- Staple Line Reinforcement
Breakup by Source:
- Natural/Biologics Products
- Synthetic Products
Breakup by Application:
- Orthopedic Surgery
- General Surgery
- Neurological Surgery
- Cardiovascular Surgery
- Gynecological Surgery
- Others
Breakup by End User:
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Product, Source, Application, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global biosurgery market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global biosurgery market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the source?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global biosurgery market and who are the key players?
- What is the degree of competition in the industry?